FDA has approved a new boxed warning for the anti-seizure drug ezogabine (Potiga) because of the potential risk of vision loss, retinal abnormalities, as well as skin, nail, mucous membrane, and sclera discoloration.
FDA has approved a new boxed warning for the anti-seizure drug ezogabine (Potiga) because of the potential risk of vision loss, retinal abnormalities, as well as skin, nail, mucous membrane, and sclera discoloration. The agency recommends that ezogabine use be limited to individuals who have not responded to alternative therapies for seizure control, and when the benefits of treatment are greater than the risks.
FDA had issued a safety warning about these risks in April.
FDA also recommends that patients’ visual acuity be tested prior to treatment with ezogabine and every 6 months while undergoing treatment with the anti-seizure drug. If visual acuity or retinal abnormalities are evident, treatment with ezogabine should be stopped. Also, if pigmentary changes occur in the skin, an alternative drug to control seizures should be considered.
The current Risk Evaluation and Mitigation Strategy (REMS) for ezogabine will be updated with the latest boxed warning, FDA said.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.